Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Article Details
- CitationCopy to clipboard
Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J
Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24.
- PubMed ID
- 16501008 [ View in PubMed]
- Abstract
Clevidipine is a short-acting dihydropyridine calcium channel antagonist under development for treatment of perioperative hypertension. Patients treated with clevidipine are likely to be comedicated. Therefore, the potential for clevidipine and its major metabolite H152/81 to elicit drug interactions by induction or inhibition of cytochrome P450 was investigated. Induction of CYP1A2, CYP2C9, and CYP3A4 was examined in primary human hepatocytes treated with clevidipine at 1, 10, and 100 microM. Clevidipine was found to be an inducer of CYP3A4, but not of CYP1A2 or CYP2C9, at the 10 microM and 100 microM concentrations of clevidipine tested. Induction response for CYP3A4 to 100 microM clevidipine was approximately 20% of that of the positive control inducer rifampicin. The response of H152/81 was similar. Using cDNA-expressed enzymes, clevidipine inhibited CYP2C9, CYP2C19, and CYP3A4 activities with IC(50) values below 10 microM, whereas CYP1A2, CYP2D6, and CYP2E1 activities were not substantially inhibited (IC(50) values >70 microM). The K(i) values for CYP2C9 and CYP2C19 were 1.7 and 3.3 microM, respectively, and those for CYP3A4 were 8.3 and 2.9 microM, using two substrates, testosterone and midazolam, respectively. These values are at least 10 times higher than the highest clevidipine concentration typically seen in the clinic. Little or no inhibition by H152/81 was found for the enzyme activities mentioned above (IC(50) values >or= 69 microM). The present study demonstrates that it is highly unlikely for clevidipine or its major metabolite to cause cytochrome P450-related drug interactions when used in the dose range required to manage hypertension in humans.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Clevidipine Cytochrome P450 2C19 Protein Humans UnknownInhibitorDetails Clevidipine Cytochrome P450 2C9 Protein Humans UnknownInhibitorDetails Clevidipine Cytochrome P450 2D6 Protein Humans UnknownSubstrateDetails Clevidipine Cytochrome P450 2E1 Protein Humans UnknownSubstrateDetails Clevidipine Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorInducerDetails Testosterone Cytochrome P450 2C19 Protein Humans UnknownSubstrateDetails Testosterone cypionate Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Testosterone enanthate Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Testosterone undecanoate Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails